• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Hot Literature: Long-term success for masitinib in dogs with MCTs

January 3, 2011
Avi Blake, DVM

Investigators from the University of Tennessee's College of Veterinary Medicine recently published their findings evaluating tumor response and overall survival rate and time for dogs with nonresectable MCTs treated with masitinib.

In an extension of a short-term study examining the response of mast cell tumors (MCTs) in dogs to masitinib (a tyrosine kinase inhibitor), investigators from the University of Tennessee's College of Veterinary Medicine recently published their findings evaluating tumor response and overall survival rate and time for dogs with nonresectable MCTs treated with masitinib.

Participating client-owned dogs had nonresectable grade 2 or 3 MCTs. Placed in randomly selected groups, the dogs received daily oral masitinib or placebo until tumor progression was detected. Treatment was extended beyond an initial short term, six-month study, at which point tumor assessment was conducted at three-month intervals for each dog until detection of tumor progression.

Masitinib administration significantly improved survival rate in these dogs, with 62.1% of the treated dogs alive at 12 months and 39.8% alive at 24 months. In comparison, only 36% of the untreated dogs were alive at 12 months and 15% at 24 months. In contrast to the poor predictive value of tumor response at six weeks, tumor control at the six-month evaluations appeared to be highly predictive for 24-month survival. Additionally, indicating a possible cure, 9% of the treated dogs achieved complete responses at 24 months. Improved long-term survival was seen regardless of c-Kit status, although, in dogs with mutated c-Kit, the improvement was more obvious.

The authors of this study emphasize that the results of this clinical study suggest that short-term response should not be the determining factor for drug approval and that tumor response is not a substitute for ascertaining data on survival. They further caution that with regard to cancer drugs used to treat MCTs in dogs, efficacy should not be concluded based on short-term tumor response, which may be entirely irrelevant.

Advertisement

Hahn KA, Legendre AM, Shaw NG, et al. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am J Vet Res 2010;71(11):1354-1361.

Link to abstract: http://avmajournals.avma.org/doi/abs/10.2460/ajvr.71.11.1354

Related Content:

Oncology
Morris Animal Foundation accepting canine cancer research proposals
Morris Animal Foundation accepting canine cancer research proposals
Morris Animal Foundation funds study on environmental toxins and lymphoma
Morris Animal Foundation funds study on environmental toxins and lymphoma
Superficial radiation therapy may serve as promising cutaneous MCT treatment
Superficial radiation therapy may serve as promising cutaneous MCT treatment

Advertisement

Latest News

Oldest aardvark in Europe passes away

Integrative approach to treating Giardia lamblia infections

Innovative digital microscopy platform is launched

Enhanced pet health and wellness app now available

View More Latest News
Advertisement